Regenerative cardiac therapy headlines this article, exploring early clinical testing and what it means for heart‑failure research. Expect concise industry context and implications.
Key Takeaways
- Phase I/II trial has begun dosing an allogeneic iPSC-derived cardiomyocyte spheroid therapy
- Independent Safety Monitoring Committee reviewed four-week data and cleared cohort continuation
- Trial will enroll 14 patients split evenly between dilated cardiomyopathy and ischemic cohorts